Company Overview and News
PTC Therapeutics is buying Agilis Biotherapeutics in a deal that has the potential to exceed $945 million with a priority review voucher thrown into the mix as well.
JAZZ PTCT UTHR ONCE
J&J (JNJ - Free Report) and Novartis (NVS - Free Report) ringed in the earnings season for the pharma space. Meanwhile, Pfizer (PFE - Free Report) and Lilly’s (LLY - Free Report) pain drug showed early positive results in a late-stage study. The FDA approved J&J’s latest HIV medicine Symtuza as well as label expansion of Pfizer’s prostate cancer drug Xtandi. In the wake of deeper political scrutiny over the high cost of prescription medicines, Novartis said it won’t raise U.
KDP NVS ABBV PFE ABBV ONCE
Fortress is building an impregnable moat by brewing a vast number of subsidiaries that focus on different market niches. Journey Medical subsidiary is providing an increasingly meaningful revenue stream.
MBIO ATXI NHLD FBIO ONCE
Novartis AG (NVS - Free Report) announced that the FDA has expanded oncology drug Kisqali’s label.
WFC WFCNP WFC.WS UNP WFC.PRL WFC.PRJ GSK ONCE WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN NVS GSK WFC.PRY WFC.PRX WFC.PRW WFC.PRV
Swiss pharma giant Novartis AG (NVS - Free Report) reported results for second-quarter 2018, wherein revenues beat estimate, driven by strong performance of Cosentyx and Entresto. However, earnings fell short.
AMGN NVS ONCE
Pfizer Inc. (PFE - Free Report) announced that it initiated a phase III, lead-in study of an experimental gene therapy treatment, fidanacogene elaparvovec, for patients with hemophilia B. Fidanacogene elaparvovec, a high-activity human coagulation factor IX gene, is a one-time treatment option.
HD PFZ 500680 PFE PFIZER ONCE BMRN
The overall bioscience market traded with a mixed sentiment for the day. Nevertheless, many equities under over coverage continued to rally.
NTLA SLDB SGMO CRSP ABEO XBI ONCE RGNX NEPH EDIT ADVM IBB ABEOW
In mid-December 2017, the U.S. Food and Drug Administration (FDA) released a guidance framework for how researchers should approach gene therapy, in terms of development and regulatory approval. This was initiated on the first-ever approval of a gene therapy for a disease caused by mutations in a specific gene. The therapy was for Spark Therapeutics’ Luxturna (voretigene neparvovec-rzyl) to treat an inherited retinal disease caused by mutations to both copies of the RPE65 gene.
Innovation holds the key in the pharma/biotech sector and most companies have been diverting their resources to develop gene therapy candidates in their goal of finding a cure for difficult and incurable diseases. In the first half of 2018, most pharma/biotech bigwigs and also a number of smaller companies scurried for a lucrative catch in the space either through licensing deals or acquisitions.
BOLD VYGR BLT SLDB ADI NVS BNTC BNIKF PFE ONCE AXON BNTCW
Benitec Biopharma could generate up to $655 million-plus in payments from licensing its preclinical gene therapy for oculopharyngeal muscular dystrophy (OPMD; pictured), and five additional Benitec gene therapy candidates for neurological disorders to to Axovant Sciences. [NIH]
BLT OXB BNTC BNIKF OXBDF ONCE BNTCW AXON
Miracles, it seems, have a high price tag. At least, if those miracles are miracle drugs. There’s no doubt that trends in gene therapy and immuno-oncology are producing drugs that are as close to miraculous as we’re likely to get, doing a great job, generally, in beating back diseases that to this point were untreatable or didn’t respond well to other therapies.
SRPT HZNP BMRN ONCE
Novartis AG (NVS - Free Report) announced that it intends to spinoff its ophthalmology division, Alcon, into a separately-traded standalone company in order to grow as a medicines company solely.
WFC WFCNP WFC.WS GILD WFC.PRL WFC.PRJ GSK ONCE WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN NVS GSK WFC.PRY WFC.PRX WFC.PRW WFC.PRV
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to ONCE / Spark Therapeutics, Inc. on message board site Silicon Investor.
as of ET